New combo pill cuts cholesterol better than standard statin alone

NCT ID NCT04669041

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 27 times

Summary

This study tested a single pill combining two cholesterol-lowering drugs (ezetimibe and rosuvastatin) against rosuvastatin alone in 305 Chinese adults whose high cholesterol was not well controlled by statins. After 8 weeks, the combo pill was more effective at lowering LDL (bad) cholesterol and helping patients reach their cholesterol goals. The treatment is meant for long-term use, not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Investigational Site Number :1560001

Beijing, 100029, China
Investigational Site Number :1560002

Tianjin, 300121, China
Investigational Site Number :1560003

Xuzhou, 221002, China
Investigational Site Number :1560005

Zhanjiang, 524001, China
Investigational Site Number :1560006

Hohhot, 010017, China
Investigational Site Number :1560007

Hohhot, 010050, China
Investigational Site Number :1560009

Wuhan, 430033, China
Investigational Site Number :1560010

Siping, 136000, China
Investigational Site Number :1560011

Zhenjiang, 212001, China
Investigational Site Number :1560014

Jilin, 132011, China
Investigational Site Number :1560015

Dalian, 116033, China
Investigational Site Number :1560019

Yueyang, 414000, China
Investigational Site Number :1560020

Jinan, 250013, China
Investigational Site Number :1560021

Beijing, 101200, China
Investigational Site Number :1560022

Xi'an, 710061, China
Investigational Site Number :1560025

Bengbu, China
Investigational Site Number :1560027

Shanghai, 200120, China
Investigational Site Number :1560029

Haikou, 570311, China
Investigational Site Number :1560033

Baotou, 014010, China
Investigational Site Number :1560034

Shenyang, 110016, China
Investigational Site Number :1560035

Wuhan, 430080, China
Investigational Site Number :1560037

Zibo, 255036, China
Investigational Site Number :1560041

Chengdu, 610041, China
Investigational Site Number :1560045

Changchun, 130021, China
Investigational Site Number :1560047

Wuhan, 430022, China
Investigational Site Number :1560052

Changsha, 410013, China
Investigational Site Number :1560053

Tianjin, 300140, China
Investigational Site Number :1560055

Nanning, 530031, China
Investigational Site Number :1560057

Yanji, 133000, China
Investigational Site Number :1560060

Chongqing, 400013, China
Investigational Site Number :1560061

Lishui, 323000, China
Investigational Site Number :1560062

Yuncheng, 044000, China
Investigational Site Number :1560063

Zhuzhou, 412007, China
Investigational Site Number :1560064

Yinchuan, 750004, China
Investigational Site Number :1560065

Yangzhou, 225001, China
Investigational Site Number :1560066

Nanjing, 210011, China
Investigational Site Number :1560067

Changchun, 130033, China
Investigational Site Number :1560068

Beijing, 100050, China
Investigational Site Number :1560070

Xi'an, 710068, China
Investigational Site Number :1560071

Liuzhou, 545006, China

Conditions

Explore the condition pages connected to this study.

HYPERCHOLESTEROLEMIA